X4 Pharmaceuticals (XFOR) Amortization of Deferred Charges (2017 - 2025)
X4 Pharmaceuticals' (XFOR) quarterly Amortization of Deferred Charges came in at $207000.0 in Q4 2025, up 2.99% YoY from $201000.0 in Q4 2024, and down 6.33% on a QoQ basis from $221000.0 in Q3 2025.
X4 Pharmaceuticals (XFOR) Amortization of Deferred Charges (2017 - 2025) Analysis & Trends
X4 Pharmaceuticals (XFOR) has 9 years of Amortization of Deferred Charges data on file, last reported at $207000.0 in Q4 2025.
- Quarterly Amortization of Deferred Charges rose 2.99% year-over-year to $207000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $865000.0 (up 1.05% YoY) and the FY2025 annual result came in at $865000.0, up 1.05% from the prior year.
- Amortization of Deferred Charges declined to $207000.0 in Q4 2025, from $221000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $265000.0 in Q4 2022 to a low of $178000.0 in Q1 2021.
- A 5-year average of $216200.0 and a median of $209500.0 in 2024 frame the typical range for Amortization of Deferred Charges.
- Annual changes were most pronounced in 2021 — Amortization of Deferred Charges jumped 49.58% — and 2024, when it decreased 20.16%.
- Tracing XFOR's Amortization of Deferred Charges over 5 years: stood at $199000.0 in 2021, then jumped by 33.17% to $265000.0 in 2022, then fell by 6.42% to $248000.0 in 2023, then slipped by 18.95% to $201000.0 in 2024, then increased by 2.99% to $207000.0 in 2025.
- The last three Amortization of Deferred Charges figures came in at $207000.0 (Q4 2025), $221000.0 (Q3 2025), and $212000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | X4 Pharmaceuticals | 533.17 Mn | 338.08 Mn | 7.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 207,000.00 |
| Dec 31, 2025 | 207,000.00 |
| Sep 30, 2025 | 221,000.00 |
| Sep 30, 2025 | 221,000.00 |
| Jun 30, 2025 | 212,000.00 |
| Jun 30, 2025 | 212,000.00 |
| Mar 31, 2025 | 225,000.00 |
| Mar 31, 2025 | 225,000.00 |
| Dec 31, 2024 | 201,000.00 |
| Dec 31, 2024 | 201,000.00 |
| Sep 30, 2024 | 194,000.00 |
| Sep 30, 2024 | 194,000.00 |
| Jun 30, 2024 | 207,000.00 |
| Jun 30, 2024 | 207,000.00 |
| Mar 31, 2024 | 254,000.00 |
| Mar 31, 2024 | 254,000.00 |
| Dec 31, 2023 | 248,000.00 |
| Dec 31, 2023 | 248,000.00 |
| Sep 30, 2023 | 243,000.00 |
| Sep 30, 2023 | 243,000.00 |